NIMble innovation - a networked model for public antibiotic trials

Antibiotic research and development (RD 2) negotiating licensing agreements for global production and distribution by industry partners; 3) using public purchasing agreements or subscription models to ensure commercially viable drug production at equitable prices. We invite stakeholders to consider our Networked Institute Model’s (NIM) benefits for unblocking the antibiotic pipeline.